O-RAN Alliance Releases First Software Code
3.12.2019 14:37:00 EET | Business Wire | Press release
Today, the O-RAN Alliance, working with the Linux Foundation, announced the O-RAN Software Community's first software code release, “Amber”.
The goal of the O-RAN Software Community is to advance opening the Radio Access Network (RAN) with a focus on the open interfaces, followed by implementations that leverage new capabilities enabled by the O-RAN specifications.
The Amber release includes initial contributions across 11 software projects. Key highlights include:
- The demonstration of the Operation and Maintenance O1 interface, including multi-vendor radio support.
- The initial release of the O-RAN unique Near Real-Time RAN Intelligent Controller. The Near-RT RIC aims at increasing network performance. It utilizes closed loop (~10ms) measurements to optimize load, energy consumption or other parameters across multiple radios. The O-RAN solution benefits from open access to local RAN data and leverages the O-RAN open architecture, including the E2 and O1 interfaces.
- 3 initial Near-RT RIC microservices (X-APPs) on network admission control, network KPI monitoring and KPI measurement.
- An initial RAN protocol stack from 4G LTE with extendable framework towards 5G standalone mode that leverages the multi-vendor O-RAN architecture with the open fronthaul interface and the F1 interface.
The Amber Release is available at the O-RAN Software Community wiki pages.
The O-RAN Software Community plans to continue rapid development of O-RAN compliant software, following the Linux Foundation 6 months release cycle.
“The first release of the O-RAN Software Community exemplifies the progress we've made as an industry, and AT&T is proud to be a member and active contributor of this effort," said Andre Fuetsch, Chairman of the O-RAN Alliance, Executive Vice President and Chief Technology Officer of AT&T. “Together, we’re driving forward open networking, software and virtualization in global wireless networks, which is critical as we shift to a 5G world.”
"We are really pleased to deliver the first release of the O-RAN Software Community with key elements in both repositories in such a short period of time," said Chih-Lin I, Co-chair of O-RAN Technical Steering Committee (TSC), Chief Scientist of China Mobile. "The Amber Release provides a good framework for the non-realtime RIC and the near-realtime RIC under Apache 2.0, as well as the O-CU and the O-DU under the FRAND-based O-RAN Software License. It demonstrates the value of close alignment between the specification work and the corresponding open source software development.”
“The TOC is proud of all the contributors who have worked hard to bring together the first release of software for an open and intelligent RAN in such a short time,” said John Murray, co-chair of the O-RAN Software Community Technical Oversight Committee and AVP advanced technologies, AT&T. “It is an exciting and evolving domain that is at the front of technology changing our world. The first release is the start of the project and we expect the contributions and functionality to continue as we grow the community of contributors and deliver additional releases in the future.”
“At Nokia we are strong proponents of O-RAN’s core principles of intelligence and openness and believe it will motivate collaboration and drive innovative new services in the industry,” said Michael Clever, Head of Cloud RAN Solutions at Nokia. “We are pleased to be contributing to the Near-RT RIC software in the O-RAN Amber Release. This and future contributions will help prove out the Near-RT RIC and pave the way for wider adoption.”
“Radisys is a champion of O-RAN Alliance and our open strategy has been a guiding beacon for us to help foster the open RAN ecosystem,” said Neeraj Patel, SVP and GM, MobilityEngine Business Unit, Radisys. “We have been working with the O-RAN Alliance and Linux Foundation to bring an open O-DU and O-CU protocol stack as part of the Amber Release. Radisys will continue to play an active role both as an enabler and integrator to fast track the operationalization and commercialization of a multi-vendor ecosystem for 5G RAN.”
“We are pleased to see the O-RAN Software Community issue its first software release, especially in such a short time since forming the project,” said Arpit Joshipura, general manager, Networking, Edge and IoT, the Linux Foundation. “The speed in which this collaboration came together represents a strong commitment across the open source networking ecosystem towards the harmonization of both open source and open standards, as well as cross-stack integration.”
About O-RAN Alliance and the O-RAN Software Community
The O-RAN Alliance is a world-wide, carrier-led effort with more than 130 member operators, vendors, and research & academic institutions operating in the Radio Access Network industry. Its mission is to drive new levels of openness in the radio access network of next generation wireless systems. Future RANs will be built on a foundation of virtualized network elements, white-box hardware and standardized interoperable interfaces that fully embrace O-RAN’s core principles of intelligence and openness.
For more information please visit www.o-ran.org.
The O-RAN Software Community was jointly created by the O-RAN Alliance and the Linux Foundation in April 2019. Its mission is to provide a software solution to support the implementation of an open and intelligent Radio Access Network (RAN), compliant with the O-RAN Alliance specifications.
For more information please visit www.o-ran-sc.org.
About the Linux Foundation
Founded in 2000, the Linux Foundation is supported by more than 1,000 members and is the world's leading home for collaboration on open source software, open standards, open data, and open hardware. Linux Foundation's projects are critical to the world's infrastructure including Linux, Kubernetes, Node.js, and more. The Linux Foundation's methodology focuses on leveraging best practices and addressing the needs of contributors, users and solution providers to create sustainable models for open collaboration. For more information please visit us at www.linuxfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005530/en/
Contact information
Zbynek Dalecky
O-RAN Alliance e.V.
pr@o-ran.org
+420 603 400 524
Jill Lovato
The Linux Foundation
jlovato@linuxfoundation.org
+1 503 703 8268
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
